TILS.L Share News (TILS)
TILS Share
TILS Share
TILS Share
TILS Share
TILS
TILS Share
TILS Broker
TILS Directors
TILS Financial
TILS
TILS Short
TILSMon, 03rd Dec 2018 11:51
LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.
The company explained that the study is a six-month trial to evaluate the tolerability and anti-tumor activity of its small molecule inhibitor, Milciclib, in liver cancer.
The company expects top line data from the trial in the second quarter of 2019.
Tiziana shares were trading up 6.3% at 67.50 pence each.
(ShareCast News) - Clinical stage biotechnology company Tiziana Life Sciences was celebrating on Wednesday, after its partnership with researchers at Cardiff University collected a fresh award. The AIM-traded company said the partnership, which has led to the development of a potential new drug for
Read more(ShareCast News) - Tiziana Life Sciences has appointed Tiziano Lazzaretti as Chief Financial Officer, effective immediately. Confirming the move on Monday, the AIM-listed biotechnology company said the appointment was not a board level position. Lazzaretti has extensive experience in the healthcare
Read more(ShareCast News) - Tiziana Life Sciences revealed the great strides it had made in the quest for cancer-fighting drugs this week, as part of its research partnership with the Cardiff University / Prifysgol Caerdydd. The AIM-listed biotechnology company, which focuses on targeted drugs to treat disea
Read more
